Powell-Tuck J, Bown R L, Chambers T J, Lennard-Jones J E
Digestion. 1981;22(5):263-70. doi: 10.1159/000198667.
A double-blind crossover trial compared prednisolone, 40 mg given orally on alternate days, with placebo as a maintenance treatment for ulcerative colitis in remission. In each patient, the study was over two periods of 3 months. Of 24 patients who completed both periods, 11 relapsed while taking placebo but not while taking prednisolone, and 1 relapsed on prednisolone but did not on placebo (p less than 0.01). 1 patient had to stop prednisolone because of hyperglycaemia; other side effects noted were mild. Prednisolone, cautiously used in this way, could be justified for the few patients who relapse frequently despite sulphasalazine.
一项双盲交叉试验比较了隔日口服40毫克泼尼松龙与安慰剂作为溃疡性结肠炎缓解期维持治疗的效果。对每位患者而言,研究为期两个3个月阶段。在完成两个阶段的24例患者中,11例在服用安慰剂时复发,但服用泼尼松龙时未复发,1例在服用泼尼松龙时复发,但服用安慰剂时未复发(P<0.01)。1例患者因高血糖不得不停用泼尼松龙;其他观察到的副作用较轻微。对于少数尽管使用柳氮磺胺吡啶仍频繁复发的患者,如此谨慎使用泼尼松龙是合理的。